Mind Medicine Inc.

MNMD

Held by 5 specialist biotech funds

High Convergence

Share on X

Fund Holdings

5 fund convergence

Avoro Capital Advisors Commodore Capital Driehaus Capital

Position Trend

Feb 17, 2026

$134.8M

4 funds

Mar 16, 2026

$67.0M

1 fund

-50% total institutional value over 2 quarters

Catalysts

No catalysts tracked.

Position Details

Avoro Capital AdvisorsNEWMar 16, 2026

Shares: 5,000,000Value: $67.0M

# Signal Note: Avoro Capital Initiates $67M Position in MNMD Avoro's $67M entry into Mind Medicine signals institutional confidence in the company's clinical pipeline, likely driven by LSD (LSD1) for anxiety disorder and MindMed's Phase 2b readout expected in 2024-2025. The position size matches Avoro's typical check for late-stage biotech bets, suggesting they view the risk/reward favorable ahead of potentially catalytic efficacy data that could validate psychedelic therapeutics as a category.

Commodore CapitalNEW

Know which insider moves are real

See who's buying with their own money vs. routine exercises
AI explains why each move matters right now

Start 7-Day Free Trial — $29/mo

Insider Signals

No insider signals tracked.

Also Held by These Funds

ALKS4 funds PTCT4 funds PTGX4 funds APLS3 funds RNA3 funds NBIX3 funds ANRO3 funds ARGX

Research Links

Yahoo Finance →SEC EDGAR →ClinicalTrials.gov →

Track specialist biotech funds, insider signals, and AI analysis

Start 7-Day Free Trial

Or get the free weekly brief:

AI Signal

AI analyst context — unlock full analysis

**Signal Note: Commodore Capital Initiates $26.8M MNMD Position** Pellini's entry suggests conviction in MNMD's clinical pipeline, likely driven by upcoming data readouts for LSD-assisted therapy in treatment-resistant depression (Phase 2b expected late 2024/early 2025) and psilocybin programs in PTSD. Given Pellini's track record scaling precision oncology at Foundation Medicine, the position size signals confidence in MNMD's ability to navigate regulatory pathways and achieve commercial viability in psychedelic-assisted therapeutics, a category seeing accelerating FDA interest.